What is Pluristem?
Pluristem Therapeutics is a pioneering biotechnology firm specializing in the development of off-the-shelf, placental-derived cell therapy products. By leveraging its proprietary PLX technology, the company targets a diverse range of indications, including orthopedic recovery, acute respiratory distress syndrome, and hematologic disorders. Its market position is defined by a robust intellectual property portfolio and strategic collaborations, such as its partnership with NASA to explore the efficacy of cell therapies in space-related medical conditions. The company's operational focus remains on advancing its lead candidates, PLX-PAD and PLX-R18, through rigorous clinical validation to establish a new standard in regenerative medicine.
How much funding has Pluristem raised?
Pluristem has raised a total of $199M across 14 funding rounds:
Other Financing Round
$250K
Other Financing Round
$1.2M
Grant
$4.2M
Grant
$2.9M
Stock Offering
$17M
Grant
$3.3M
Share Placement
$30M
Multiple Rounds
$49M
Stock Offering
$20M
Debt
$56.2M
Share Placement
$15M
Other Financing Round (2010): $250K, investors not publicly disclosed
Other Financing Round (2010): $1.2M, investors not publicly disclosed
Grant (2014): $4.2M supported by Israeli Ministry of Economy, Office of the Chief Scientist
Grant (2015): $2.9M featuring Israeli Ministry of Economy, Office of the Chief Scientist
Stock Issuance/Offering (2015): $17M, investors not publicly disclosed
Grant (2016): $3.3M with participation from Israeli Ministry of Economy, Office of the Chief Scientist
Share Placement (2016): $30M led by Innovative Medical Management
Stock Issuance/Offering (2017): $17.3M, investors not publicly disclosed
Grant (2017): $8.7M featuring Horizon 2020 Program
Grant (2017): $7.9M backed by Horizon 2020 Program
Stock Issuance/Offering (2017): $15.1M, investors not publicly disclosed
Stock Issuance/Offering (2019): $20M, investors not publicly disclosed
Debt (2020): $56.2M supported by European Investment Bank
Share Placement (2020): $15M, investors not publicly disclosed
Key Investors in Pluristem
European Investment Bank
Established in 1958 and headquartered in Luxembourg, the European Investment Bank is the European Union's nonprofit long-term lending and finance institution, focusing on supporting sustainable growth and innovation.
Israeli Ministry of Economy, Office of the Chief Scientist
A government body dedicated to fostering industrial research and development within Israel by providing grants and strategic support to high-potential technology firms.
Horizon 2020 Program
The European Union's research and innovation funding program, designed to drive economic growth and create jobs by supporting breakthrough scientific projects.
What's next for Pluristem?
Looking ahead, Pluristem is positioned to capitalize on its late-stage clinical assets, with a primary focus on completing Phase III trials for its lead candidates. The strategic deployment of the $15M will likely be directed toward accelerating manufacturing capabilities and expanding global clinical trial footprints, particularly in key markets like South Korea. As the company matures, the focus will shift from research-heavy development to commercialization readiness, necessitating continued engagement with regulatory bodies and potential pharmaceutical partners. The firm's ability to maintain its technological edge in the competitive cell therapy landscape will be critical as it moves toward potential market authorization and long-term value creation for stakeholders.
See full Pluristem company page
